Industry: Biotechnology

Sector: Healthcare

Eledon Pharmaceuticals, Inc., clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis (ALS), and requiring an organ or cell-based transplant. Its lead product candidate includes Tegoprubart, an anti-CD40L antibody with high affinity for CD40 ligand, which is in Phase 2 clinical trial for kidney transplantation, IgA nephropathy, and amyotrophic lateral sclerosis, as well as preclinical Phase for xenotransplantation. The company is also developing AT-2001, which is preclinical Phase for autoimmune indications. It has a collaboration agreement with eGenesis, Inc. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.

Eledon Pharmaceuticals Inc is evaluated using Mavefund's quality framework: growing earnings, durable profit margins, conservative leverage, strong return on equity, and disciplined share repurchases.